Skip to content
CityAM Canada
  • Business
  • Markets
  • Tech
  • AI
  • Economics
  • Opinion
  • Cities
Monday 29 June 2026 3:19 pm  |  Updated:  Monday 29 June 2026 4:09 pm

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

By: Business Wire

Add as a preferred source on Google

For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company’s long-term strategy, with a focus on expanding Medisca’s global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day.

“When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “That purpose continues to guide us. As we begin this next chapter, we’ll keep investing in our people, our partnerships, and the innovation that will help shape the future of Medisca and the pharmaceutical compounding industry.”

Working alongside Vice-Chair Maria Zaccardo and Medisca’s C-Suite, Dos Santos will continue to guide the company’s strategic direction as Medisca continues to expand globally and invest in its long-term growth.

“For over three decades, Medisca has grown by staying true to its purpose while continuing to evolve with the needs of healthcare professionals,” said Maria Zaccardo, Vice-Chair of Medisca. “As we look ahead, we remain focused on supporting our customers, investing in our people, and continuing to strengthen Medisca for the future.”

As part of this leadership transition, Sanjay Goorachurn has stepped down from his role as Chief Executive Officer. Medisca thanks Sanjay for his dedication and contributions to the organization and wishes him continued success.

As Medisca continues to grow globally, the company remains committed to empowering personalized wellness for all by expanding the products, technologies, education, and expertise that help healthcare professionals deliver better patient care around the world.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.Medisca.com and follow us on LinkedIn, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629786213/en/

Contact

Medisca Communications
communications@medisca.com
1-800-665-6334

TweetText

As Medisca enters its next chapter, we remain committed to raising the standard of pharmaceutical compounding and supporting healthcare professionals with the products, knowledge, and innovation they need to deliver better patient care.

Company Logo
Company Logo
Read more

LivaNova Appoints Anne Liddy as Chief Legal Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Personnel

Trending Articles

  • Exclusive: Big Four giant KPMG to cut more jobs

  • Music tycoon Simon Cowell sued by prominent City lawyer

  • The former African gold miner taking on the billionaire Issa brothers

  • Tesco ‘in talks’ to exit eastern Europe

  • As it happened: FTSE 100 slump as oil soars; Trump says Iran will be ‘hit hard’ tonight

More from CityAM

  • LivaNova Appoints Anne Liddy as Chief Legal Officer

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions

    Business Wire
  • Real Chemistry Unifies Omnichannel Offering as Real Chemistry Media, a Technology-led, Healthcare-focused Practice of the Future

    Business Wire
  • Boots eyes £7.5bn sale in blow to hopes of London IPO

    Retail
    Boots remains one of the group’s best performing business lines, with a London float suggested as recently as last year. (Photo by Oli Scarff/Getty Images)
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Straive Acquires NextGen Invent to Boost Data & AI Operationalization Capabilities

    Business Wire
  • Jette Nygaard-Andersen Joins LivaNova Board as a New Director

    Business Wire

CityAM Canada — business, markets and opinion for Canadian readers.

Published by CityAM Publishing
3 Borden Street #301, Toronto, Ontario M5S 2M8, Canada
Contact us ›

Sections

  • Business
  • Markets
  • Tech
  • AI
  • Economics
  • Opinion
  • Cities

Company

  • About
  • Newsroom
  • Contact

Legal

  • Editorial Policy
  • Corrections Policy
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 CityAM Canada. All rights reserved.
Terms · Privacy · Cookies